Assertio Therapeutics Inc Net Assets
Assertio Therapeutics Inc net assets. Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) has net assets worth $75.63 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($211.30 Million) and total liabilities ($135.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Assertio Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $75.63 Million |
| % of Total Assets | 35.79% |
| Annual Growth Rate | N/A |
| 5-Year Change | -8.26% |
| 10-Year Change | -62.54% |
| Growth Volatility | 140.36 |
Net Assets of Assertio Therapeutics Inc (1996–2025)
Net assets of Assertio Therapeutics Inc from 1996 to 2025. This chart illustrates how Assertio Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See ASRT equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Assertio Therapeutics Inc (1996–2025)
The table below shows the annual net assets of Assertio Therapeutics Inc from 1996 to 2025. For live market cap and overall valuation, see ASRT stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $93.95 Million | -22.41% |
| 2024-12-31 | $121.08 Million | -12.26% |
| 2023-12-31 | $138.00 Million | -38.86% |
| 2022-12-31 | $225.72 Million | +120.40% |
| 2021-12-31 | $102.41 Million | +84.48% |
| 2020-12-31 | $55.51 Million | -4.22% |
| 2019-12-31 | $57.96 Million | -73.70% |
| 2018-12-31 | $220.34 Million | +29.99% |
| 2017-12-31 | $169.51 Million | -32.41% |
| 2016-12-31 | $250.79 Million | -20.40% |
| 2015-12-31 | $315.06 Million | -13.55% |
| 2014-12-31 | $364.45 Million | +165.21% |
| 2013-12-31 | $137.42 Million | +63.72% |
| 2012-12-31 | $83.94 Million | -20.75% |
| 2011-12-31 | $105.92 Million | +358.40% |
| 2010-12-31 | $23.11 Million | +46.93% |
| 2009-12-31 | $15.73 Million | -52.57% |
| 2008-12-31 | $33.15 Million | -27.17% |
| 2007-12-31 | $45.52 Million | +266.81% |
| 2006-12-31 | $-27.29 Million | -503.62% |
| 2005-12-31 | $6.76 Million | -19.54% |
| 2004-12-31 | $8.40 Million | -75.70% |
| 2003-12-31 | $34.58 Million | +639.08% |
| 2002-12-31 | $-6.41 Million | -334.19% |
| 2001-12-31 | $-1.48 Million | -132.21% |
| 2000-12-31 | $4.59 Million | -50.25% |
| 1999-12-31 | $9.22 Million | +0.20% |
| 1998-12-31 | $9.20 Million | +124.39% |
| 1997-12-31 | $4.10 Million | +1125.00% |
| 1996-12-31 | $-400.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Assertio Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 70239900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Assertio Therapeutics Inc Net Assets Breakdown (December 2025)
Assertio Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $797.45 Million | 848.78% |
| Total Equity | $93.95 Million | 100.00% |
Assertio Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Assertio Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BurTech Acquisition Corp
NASDAQ:BRKH
|
$151.93 Million |
|
Meghmani Organics Limited
NSE:MOL
|
$151.95 Million |
|
Amplify Energy Corp
NYSE:AMPY
|
$152.19 Million |
|
AYER Holdings Bhd
KLSE:2305
|
$152.22 Million |
|
Cnergenz Bhd
KLSE:0246
|
$151.83 Million |
|
Seoho Electric Co.Ltd
KQ:065710
|
$151.80 Million |
|
JIUMAOJIU INTL HLDGS LTD
F:3YU
|
$151.70 Million |
|
Koenig & Bauer AG
XETRA:SKB
|
$151.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Assertio Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 121,081,000 to 93,952,000, a change of -27,129,000 (-22.4%).
- Net loss of 30,375,000 reduced equity.
- Share repurchases of 189,000 reduced equity.
- Other factors increased equity by 3,435,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.38 Million | -32.33% |
| Share Repurchases | $189.00K | -0.2% |
| Other Changes | $3.44 Million | +3.66% |
| Total Change | $- | -22.41% |
Book Value vs Market Value Analysis
This analysis compares Assertio Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.60x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $-5.76 | $23.50 | x |
| 1997-12-31 | $55.35 | $23.50 | x |
| 1998-12-31 | $87.37 | $23.50 | x |
| 1999-12-31 | $85.43 | $23.50 | x |
| 2000-12-31 | $37.54 | $23.50 | x |
| 2001-12-31 | $-8.67 | $23.50 | x |
| 2002-12-31 | $-26.28 | $23.50 | x |
| 2003-12-31 | $84.82 | $23.50 | x |
| 2004-12-31 | $14.56 | $23.50 | x |
| 2005-12-31 | $10.19 | $23.50 | x |
| 2006-12-31 | $-39.44 | $23.50 | x |
| 2007-12-31 | $58.92 | $23.50 | x |
| 2008-12-31 | $40.78 | $23.50 | x |
| 2009-12-31 | $18.31 | $23.50 | x |
| 2010-12-31 | $25.98 | $23.50 | x |
| 2011-12-31 | $113.30 | $23.50 | x |
| 2012-12-31 | $90.10 | $23.50 | x |
| 2013-12-31 | $143.28 | $23.50 | x |
| 2014-12-31 | $21.99 | $23.50 | x |
| 2015-12-31 | $20.96 | $23.50 | x |
| 2016-12-31 | $16.37 | $23.50 | x |
| 2017-12-31 | $162.20 | $23.50 | x |
| 2018-12-31 | $205.89 | $23.50 | x |
| 2019-12-31 | $49.18 | $23.50 | x |
| 2020-12-31 | $31.77 | $23.50 | x |
| 2021-12-31 | $35.59 | $23.50 | x |
| 2022-12-31 | $61.93 | $23.50 | x |
| 2023-12-31 | $29.14 | $23.50 | x |
| 2024-12-31 | $19.06 | $23.50 | x |
| 2025-12-31 | $14.67 | $23.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Assertio Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -25.59%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.84x
- Recent ROE (-32.33%) is above the historical average (-65.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 0.00% | -166.67% | 1.00x | 0.00x | $-460.00K |
| 1997 | -29.27% | -200.00% | 0.13x | 1.12x | $-1.61 Million |
| 1998 | -30.43% | -350.00% | 0.08x | 1.12x | $-3.72 Million |
| 1999 | -186.68% | -14921.74% | 0.01x | 2.43x | $-18.13 Million |
| 2000 | -211.57% | -546.27% | 0.20x | 1.90x | $-10.16 Million |
| 2001 | 0.00% | -479.13% | 0.42x | 0.00x | $-17.45 Million |
| 2002 | 0.00% | -812.35% | 0.07x | 0.00x | $-12.85 Million |
| 2003 | -86.81% | -3056.56% | 0.02x | 1.38x | $-33.47 Million |
| 2004 | -319.80% | -13266.41% | 0.01x | 2.72x | $-27.71 Million |
| 2005 | -361.89% | -555.40% | 0.07x | 9.82x | $-25.14 Million |
| 2006 | 0.00% | -415.23% | 0.18x | 0.00x | $-36.93 Million |
| 2007 | 108.13% | 75.05% | 0.81x | 1.77x | $44.67 Million |
| 2008 | -46.16% | -43.92% | 0.37x | 2.87x | $-18.62 Million |
| 2009 | -139.95% | -38.12% | 0.63x | 5.82x | $-23.58 Million |
| 2010 | 16.86% | 4.82% | 0.93x | 3.77x | $1.59 Million |
| 2011 | 66.77% | 53.19% | 0.81x | 1.55x | $60.13 Million |
| 2012 | -35.48% | -32.79% | 0.64x | 1.69x | $-38.17 Million |
| 2013 | 31.52% | 32.27% | 0.26x | 3.70x | $29.57 Million |
| 2014 | 36.15% | 33.75% | 0.55x | 1.95x | $95.32 Million |
| 2015 | -24.04% | -22.10% | 0.25x | 4.33x | $-107.24 Million |
| 2016 | -35.38% | -19.46% | 0.37x | 4.89x | $-113.80 Million |
| 2017 | -60.47% | -26.92% | 0.37x | 6.13x | $-119.45 Million |
| 2018 | 16.75% | 11.84% | 0.33x | 4.23x | $14.87 Million |
| 2019 | -374.76% | -94.63% | 0.44x | 9.10x | $-223.00 Million |
| 2020 | -50.70% | -26.04% | 0.36x | 5.46x | $-33.70 Million |
| 2021 | -1.25% | -1.15% | 0.34x | 3.19x | $-11.52 Million |
| 2022 | 48.57% | 70.17% | 0.38x | 1.83x | $87.05 Million |
| 2023 | -240.53% | -218.28% | 0.53x | 2.08x | $-345.74 Million |
| 2024 | -17.82% | -17.27% | 0.44x | 2.35x | $-33.69 Million |
| 2025 | -32.33% | -25.59% | 0.44x | 2.84x | $-39.77 Million |
Industry Comparison
This section compares Assertio Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $86,713,726
- Average return on equity (ROE) among peers: 26.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Assertio Therapeutics Inc (ASRT) | $75.63 Million | 0.00% | 1.79x | $151.86 Million |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $335.50 Million | -73.41% | 0.53x | $143.73 Million |
| Akanda Corp (AKAN) | $4.28 Million | -95.78% | 0.85x | $584.11K |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $194.43 Million |
| Alkermes Plc (ALKS) | $18.84 Million | -398.98% | 9.71x | $7.67 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.25 Billion |
| Amphastar P (AMPH) | $233.44 Million | 7.75% | 0.36x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $5.96 Million | 1208.40% | 615.85x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $135.63 Million | 15.17% | 0.15x | $260.30 Million |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more